Publications
210
Citations
4,585
Est. group size
~16
Recurring co-author estimate
Active years
48
Publishing since 1979
László Farkas studies the biology of pulmonary arterial hypertension and related lung diseases, focusing on how blood vessel lining cells (endothelium) and lung pericytes malfunction, and how immune signaling, genetic factors, and cell stress pathways contribute to disease. The work combines molecular and cellular laboratory studies (using mouse models, endothelial cell cultures, and lung tissue) to identify potential biomarkers and therapeutic targets for pulmonary vascular and fibrotic lung disease.
Publication output has grown fairly steadily over the past decade, rising from about 5 papers per year in 2017 to a peak of 13 in 2023, with continued strong activity (6-8 per year) through 2025-2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Global knockout of melanoma differentiation-associated protein 5 protects mice from chronic hypoxia/SU5416-induced pulmonary hypertension - Supplemental Methods and Data
Open MIND · 2026
- Global knockout of melanoma differentiation-associated protein 5 protects mice from chronic hypoxia/SU5416-induced pulmonary hypertension - Supplemental Methods and Data
Zenodo (CERN European Organization for Nuclear Research) · 2026
- Global knockout of melanoma differentiation-associated protein 5 protects mice from chronic hypoxia/SU5416-induced pulmonary hypertension - Supplemental Methods and Data
Zenodo (CERN European Organization for Nuclear Research) · 2026
- von Willebrand Factor: An Unhealthy Bond between Lung Endothelium and Pulmonary Fibrosis
American Journal of Respiratory Cell and Molecular Biology · 2025
- Liposomes-Encapsulating Double-Stranded Nucleic Acid (Poly I:C) for Head and Neck Cancer Treatment
ACS Pharmacology & Translational Science · 2024
- When a DEAD-Box Protein is the Key: A Novel Role for DDX5 in Lung Pericyte Dysfunction
American Journal of Respiratory Cell and Molecular Biology · 2024
- Using extracellular matrix derived from sugen-chronic hypoxia lung tissue to study pulmonary arterial hypertension
Frontiers in Pharmacology · 2023
- Circling In on Pulmonary Arterial Hypertension: Is It Time to Consider Circular RNA circ_0016070 as a Biomarker and Target for Therapy?
Journal of the American Heart Association · 2022
- Hypoxia Signaling and p53 Regulate Expression of Endosomal GTPase RAB7 in Pulmonary Artery Endothelial Cells in PAH
2022
- Epigenetic Regulation of Endothelial Dysfunction and Inflammation in Pulmonary Arterial Hypertension
International Journal of Molecular Sciences · 2021
- The Endothelium Is in Shock and IFN-α/STAT1 Signaling Is to Blame
American Journal of Respiratory Cell and Molecular Biology · 2021
- Deficiency of the Endosomal Small GTPase Rab7 Contributes to Endothelial Dysfunction in Pulmonary Arterial Hypertension
2021
- Endothelial Loss of P53 Promotes Endothelial Dysfunction via Impaired TLR3-BMP Axis in Pulmonary Arterial Hypertension
2021
- When Innate Immunity Meets Angiogenesis—The Role of Toll-Like Receptors in Endothelial Cells and Pulmonary Hypertension
Frontiers in Medicine · 2020
- A Novel Peptide for Immunomodulation in Pulmonary Arterial Hypertension
American Journal of Respiratory and Critical Care Medicine · 2019
- American Journal of Respiratory Cell and Molecular Biology×5
- bioRxiv (Cold Spring Harbor Laboratory)×5
- American Journal of Respiratory and Critical Care Medicine×4
- Circulation×3
- Physiological Reports×2
- Daniela Farkas
Medicine · The Ohio State University
- Amanda Fisher
Medicine · Indiana University
- Ana L. Mora
Medicine · The Ohio State University
- Mauricio Rojas
Medicine · The Ohio State University
- P. Finnegan
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile